Identification of Vulnerable Coronary Plaques and Vulnerable Patients: Implications for Clinical Care and Research

Brigham and Women's Hospital Cardiovascular Grand Rounds lecture by James Muller on " Identification of Vulnerable Coronary Plaques and Vulnerable Patients: Implications for Clinical Care and Research"

Spectrawave Raises $13.2M for Intracoronary Imaging Solution

SpectraWave today announced a $13.2 million Series A-2 financing to support completion of product development and regulatory filing for its flagship intracoronary imaging product, designed to help physicians optimize coronary stenting interventions and limit future adverse events. The funding round is led by prior investor Deerfield Management, and includes follow-on investment from prior unnamed seed investors. Coronary artery disease (CAD), the buildup of plaque in the wall of the coronary arteries that supply blood to the heart, causes 9 million deaths worldwide each year. In CAD, patients can undergo stent placement to relieve symptoms, but one in five patients can experience a major adverse event. SpectraWAVE is developing a medical imaging platform that combines two state-of-the-art technologies providing high resolution plaque structure and content in coronary blood vessels. The imaging data aids interventional cardiologists during stent optimization and in their assessment o...

SpectraWAVE Appoints Eman Namati, Ph.D., as Chief Executive Officer to Lead Development and Launch of Flagship Technology

New Imaging Technology to Improve Coronary Artery Disease Patient Outcomes SpectraWAVE, Inc., a development-stage medical imaging company focused on improving coronary artery disease (CAD) outcomes with photonics, is pleased to announce that Eman Namati, Ph.D., has been appointed Chief Executive Officer. Dr. Namati brings more than a decade of experience leading the development and launch of highly technical medical imaging products. Dr. Namati said, “The Board, founders, and team at SpectraWAVE have been an inspiring group to join. They are talented, experienced, and purpose-driven, which will be key as we move towards the launch of our new photonic imaging technology for coronary artery disease. Our flagship technology will define our clinical impact and growth, and we are working hard to bring that solution to the market to help as many patients as possible with coronary artery disease.” “SpectraWAVE has the opportunity to help millions of patients worldwide,&rd...

Intravascular optical coherence tomography

Intravascular optical coherence tomography (IVOCT) began at MIT in the early 1990’s with the recognition that OCT could be used for clinical applications other than ophthalmology. Initial steps made there towards IVOCT feasibility included the acquisition of cadaver arterial images demonstrating the capacity of OCT to visualize depth-resolved architectural detail of plaque 5 and the development of the first mechanical scanning catheter. 6 Early histopathologic correlation studies from cadaver arteries demonstrated that IVOCT was capable of distinguishing the major fibrous, fibrocalcific, and lipid-rich plaque types and also potentially identifying inflammation as manifested by macrophage accumulations. 7, 8 Data from the first patients 1 acquired at Massachusetts General Hospital and in Korea (Asan Medical Center, St. Mary’s Hospital) at the turn of the millennium showed the potential of this technology to obtain high-resolution images of coronary plaque pathology, but t...


Organizations in the News

OCT Companies in the News

Picture Gallery